美国于2025年启动了一项新的药物定价政策,要求降低价格,以与其他发达国家保持一致。 The U.S. launched a new drug pricing policy in 2025, requiring lower prices aligned with other developed nations.

2025年,美国政府推行了最惠国药品定价政策,使美国处方药价格与其他发达国家的最低价格相一致。 In 2025, the U.S. government advanced a Most Favored Nation (MFN) drug pricing policy, aligning U.S. prescription drug prices with the lowest rates in other developed nations. 根据5月的一项行政命令,医疗保健和医疗补助服务中心确定了价格目标,导致在11月前与五个制药厂达成自愿协议。 Under a May executive order, the Centers for Medicare and Medicaid Services (CMS) set price targets, leading to voluntary agreements with five pharmaceutical manufacturers by November. 这些交易要求制造商向医疗补助方案提供最惠国定价,包括新推出药品,并支持通过TrumpRx.gov直接对消费者的销售。 These deals require manufacturers to offer MFN pricing to Medicaid programs, include new drug launches, and support direct-to-consumer sales via TrumpRx.gov. 作为交换,一些公司收到第232节延迟征收的关税和林业发展局专员国家优先券,以加快药物审查。 In exchange, some companies received delayed Section 232 tariffs and FDA Commissioner National Priority Vouchers to speed up drug reviews. 行政部门表示,如果不实现更广泛的遵守,将采取进一步的管制行动。 The administration signaled further regulatory action if broader compliance is not achieved. 该政策是降低药物成本的更广泛努力的一部分,标志着美国保健和贸易战略的重大转变,对国际供应链和药品定价具有潜在影响。 The policy, part of a broader effort to reduce drug costs, marks a significant shift in U.S. healthcare and trade strategy, with potential impacts on international supply chains and pharmaceutical pricing.